FENG Yu, ZHANG Kaigui, ZHU Maocai, ZOU Zhaohua, QING Wei. Risk factor analysis and personalized prevention strategies for renal anemia in hemodialysis patients with end-stage kidney disease[J]. Journal of Clinical Medicine in Practice, 2024, 28(24): 103-109. DOI: 10.7619/jcmp.20244557
Citation: FENG Yu, ZHANG Kaigui, ZHU Maocai, ZOU Zhaohua, QING Wei. Risk factor analysis and personalized prevention strategies for renal anemia in hemodialysis patients with end-stage kidney disease[J]. Journal of Clinical Medicine in Practice, 2024, 28(24): 103-109. DOI: 10.7619/jcmp.20244557

Risk factor analysis and personalized prevention strategies for renal anemia in hemodialysis patients with end-stage kidney disease

More Information
  • Received Date: September 28, 2024
  • Revised Date: November 03, 2024
  • Objective 

    To explore the risk factors for renal anemia in hemodialysis patients with end-stage kidney disease (ESKD).

    Methods 

    A total of 48 ESKD patients undergoing hemodialysis in our hospital from December 2021 to December 2022 were selected as study objects. They were divided into renal anemia group (86 cases) and non-anemia group (62 cases) based on hemoglobin (Hb) levels and diagnostic criteria for renal anemia. Clinical data between the two groups were compared. Random forest algorithm and multivariate Logistic regression analysis were used to screen for factors influencing renal anemia, and a multivariate Logistic regression model was established. Cross-validation was also employed to verify the stability of the model. A risk stratification system was developed, and patients were stratified based on cut-off values obtained from X-Tile software. The areas under the receiver operating characteristic (ROC) curves were used to evaluate the discrimination ability of the multivariate Logistic regression model and the risk stratification system.

    Results 

    Among 148 ESKD patients, the incidence of renal anemia was 58.11% (86/148). Hypertension, increased neutrophil-to-lymphocyte ratio (NLR), elevated C-reactive protein (CRP), increased serum ferritin (SF), and elevated intact parathyroid hormone (iPTH) were identified as risk factors for renal anemia (P < 0.05). Administration of α-calcidol, increased erythropoietin (EPO), elevated triglyceride (TG), and increased serum albumin (ALB) were protective factors (P < 0.05). The goodness-of-fit test for the multivariate Logistic regression model showed a Nagelkerke R2 of 0.593. Based on the cut-off values for risk scores obtained from X-Tile software, patients were stratified into low-risk group (< 4 points, 29 cases), medium-risk group (4 to < 7 points, 64 cases), and high-risk group (≥7 points, 55 cases), with renal anemia incidence rates of 24.14%, 57.81%, and 76.36%, respectively. The difference in renal anemia incidence rates among the three groups was statistically significant (P < 0.001). In the training set, the areas under the ROC curves for the multivariate Logistic regression model and the risk stratification system were 0.826 and 0.811, respectively, and were 0.804 and 0.789, respectively in the validation set.

    Conclusion 

    The occurrence of renal anemia in hemodialysis patients with ESKD is influenced by various factors, including hypertension, NLR, CRP, etc.

  • [1]
    JANKOWSKI J, FLOEGE J, FLISER D, et al. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options[J]. Circulation, 2021, 143(11): 1157-1172. doi: 10.1161/CIRCULATIONAHA.120.050686
    [2]
    LIU P, QUINN R R, LAM N N, et al. Accounting for age in the definition of chronic kidney disease[J]. JAMA Intern Med, 2021, 181(10): 1359-1366. doi: 10.1001/jamainternmed.2021.4813
    [3]
    GERRITS T, BROUWER I J, DIJKSTRA K L, et al. Endoglin is an important mediator in the final common pathway of chronic kidney disease to end-stage renal disease[J]. Int J Mol Sci, 2022, 24(1): 646. doi: 10.3390/ijms24010646
    [4]
    WANG X F, SHI Q Y, MO Y Z, et al. Palliative care needs and symptom burden in younger and older patients with end-stage renal disease undergoing maintenance hemodialysis: a cross-sectional study[J]. Int J Nurs Sci, 2022, 9(4): 422-429.
    [5]
    GONG Y, XIE L Y, YU S Q. Long-term In-center nocturnal hemodialysis improves renal Anemia and malnutrition and life quality of older patients with chronic renal failure[J]. Clin Interv Aging, 2022, 17: 915-923. doi: 10.2147/CIA.S358472
    [6]
    TSAI M H, SU F Y, CHANG H Y, et al. The effect of statin on Anemia in patients with chronic kidney disease and end-stage kidney disease: a systematic review and meta-analysis[J]. J Pers Med, 2022, 12(7): 1175. doi: 10.3390/jpm12071175
    [7]
    KU E, DEL VECCHIO L, ECKARDT K U, et al. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2023, 104(4): 655-680. doi: 10.1016/j.kint.2023.05.009
    [8]
    孙雪峰. 《中国肾性贫血诊疗的临床实践指南》解读[J]. 中国实用内科杂志, 2021, 41(9): 785-788.
    [9]
    UMBOH O, MOIES E S, PALAR S. The effect of Anemia and hypoalbuminemia on six-months hospitalization risk in end stage chronic kidney disease patients undergoing hemodialysis: a retrospective cohort study[J]. Acta Med Indones, 2023, 55(2): 136-141.
    [10]
    AGORO R, WHITE K E. Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics[J]. Curr Opin Nephrol Hypertens, 2022, 31(4): 320-325. doi: 10.1097/MNH.0000000000000797
    [11]
    GUTIÉRREZ O M. Treatment of iron deficiency Anemia in CKD and end-stage kidney disease[J]. Kidney Int Rep, 2021, 6(9): 2261-2269. doi: 10.1016/j.ekir.2021.05.020
    [12]
    RASHIDI A, GARIMELLA P S, AL-ASAAD A, et al. Anemia management in the cancer patient with CKD and end-stage kidney disease[J]. Adv Chronic Kidney Dis, 2022, 29(2): 180-187. e1. doi: 10.1053/j.ackd.2022.03.005
    [13]
    王静, 温向琼, 康婷, 等. 维持性血液透析患者肾性贫血与中性粒细胞/淋巴细胞比值的相关性[J]. 西部医学, 2023, 35(2): 242-246. doi: 10.3969/j.issn.1672-3511.2023.02.017
    [14]
    李霞, 陈育青. 影响维持性血液透析患者促红细胞生成素抵抗的因素分析[J]. 重庆医学, 2022, 51(9): 1554-1557. doi: 10.3969/j.issn.1671-8348.2022.09.024
    [15]
    刘海飞, 赵晓倩, 李兆婷, 等. 老年维持性血液透析病人肾性贫血现状调查及影响因素分析[J]. 实用老年医学, 2022, 36(4): 345-349.
    [16]
    韩蓓, 韩俊岭, 曹靖昊, 等. 全段成纤维细胞生长因子23与维持性血液透析患者肾性贫血的相关性研究[J]. 实用临床医药杂志, 2021, 25(21): 114-118. doi: 10.7619/jcmp.20213812
    [17]
    吕晴, 陈卫东, 刘磊. 维持性血液透析患者肾性贫血的多因素分析及相关性研究[J]. 中华全科医学, 2021, 19(5): 871-874.
    [18]
    朱燕. 长期维持性血液透析患者发生肾性贫血的危险因素分析[J]. 现代医学与健康研究电子杂志, 2022, 6(14): 24-26.
  • Cited by

    Periodical cited type(11)

    1. 王轶. 注射用盐酸倍他司汀治疗眩晕症的临床效果及对炎性因子的影响. 临床合理用药. 2024(02): 48-51 .
    2. 曾智本,吴新风. 三联疗法联合倍他司汀治疗耳石症复位后残余头晕的效果观察. 实用临床医药杂志. 2024(13): 92-97 . 本站查看
    3. 李欣龙,袁琳. 倍他司汀联合阿托伐他汀用于颈动脉斑块伴眩晕患者的疗效观察. 大医生. 2023(05): 41-43 .
    4. 栗冰洁. 半夏白术天麻汤联合氟桂利嗪胶囊治疗周围性眩晕患者的效果. 承德医学院学报. 2023(02): 124-127 .
    5. 刘钢招,钟丽,沈娟. 倍他司汀联合天麻钩藤饮治疗眩晕症的疗效及对脑血流动力学的影响. 现代诊断与治疗. 2023(05): 644-646 .
    6. 金赢政,井睿智,李金江. 天麻钩藤饮联合针灸治疗后循环缺血性眩晕临床研究. 新中医. 2023(22): 53-58 .
    7. 刘秀. 倍他司汀联合盐酸氟桂利嗪对颈性眩晕患者眩晕症状及血液流变学的影响. 现代医学与健康研究电子杂志. 2023(23): 47-49 .
    8. 章恒端,叶旭星,胡建海. 半夏白术天麻汤联合耳穴埋豆治疗颈性眩晕的临床效果. 中国医师杂志. 2022(12): 1832-1836 .
    9. 冷静,李红,王孝佳,董阳,韩丽丽. 后循环缺血继发眩晕给予倍他司汀及氟桂利嗪的临床干预效果评析. 中外医疗. 2022(29): 89-92 .
    10. 许电,陈慧珍,邓恺伦. 针刺联合甲磺酸倍他司汀片对颈性眩晕患者疗效及椎基底动脉血流动力学的影响. 医学理论与实践. 2021(18): 3163-3164 .
    11. 李晓,贺永雄,李世珅. 不同方法治疗颈性眩晕症的临床疗效比较. 内蒙古医学杂志. 2020(12): 1423-1424 .

    Other cited types(19)

Catalog

    Article views (30) PDF downloads (5) Cited by(30)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return